Presented at EASD 2026, the 52-week analysis showed a 1.46 point bigger weight drop. A GlobalData analyst says head-to-head trials are still needed.
Recap by typeshit. Full story at Pharmafile.
Avi Roy points out that the largest test so far found no memory benefit from the drug in Ozempic, despite hopes raised by health record studies.
Balwinder Singh and Raman Baweja link GLP-1 use to less kidney replacement therapy in bipolar patients with CKD, and flag lithium toxicity cases.
Yale Medicine says 5% to 10% of people on GLP-1 weight loss drugs see little result, and points to diet as one factor that can blunt the effect.
24:26
A doctor's explainer sorting peptides into eight broad categories. An evergreen overview for anyone still learning the basics.
The Korean drugmaker says it will show two sets of findings on its oral semaglutide for obesity and diabetes at the AAPS annual meeting.
Started in 20-month-old female mice, the drug matched many benefits of calorie restriction and beat it on spatial memory and glucose control, the authors report.
Loading…